Evaluation effect of Dinvl for Covid19 infection

INTERVENTION: Intervention 1: Intervention group:??Dinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company. Intervention 2: Control group: Routine tablets is given daily for seven days. CONDITION: Pneumonia induced by covid19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Time to clinical recovery. Timepoint: Control clinical signs daily until discharge from the hospital. Method of measurement: Fever control with thermometer, oxygen saturation control with pulsoximetry. SECONDARY OUTCOME: 14 days readmission after discharge. Timepoint: Up to 14 days after discharge. Method of measurement: All patients will be given a contact number to notify them if they are hospitalized again. All patients will be monitored by phone weekly for up to 4 weeks after the first day they are admitted. INCLUSION CRITERIA: Patients up18 years old hospitalized Patient with SpO2:85‐89% on room air at admission (if correct with nasal O2 maximum 6 liter/min to SpO2>=90 ) Patients with SpO2: 90‐93% and RR>=30 clinical compatible patients with positive RT‐PCR test or consistent HRCT to covid19 pneumonia Sign the study participation form